

PUBLIC SUMMARY DOCUMENT

Product: Esteem[®] + Convex Urostomy

Applicant: ConvaTec (Australia) Pty Ltd

Date of SPAP Meeting: 11 April 2016

1. Proposed Listing on the Stoma Appliance Scheme

The applicant, ConvaTec, sought listing of the Esteem[®] + Convex Urostomy One-Piece pouch with Convex Baseplate, in subgroup 3(b) of the Stoma Appliance Scheme (SAS) Schedule. The product including seven variants, was proposed for listing at the unit price of \$6.373 with a maximum monthly quantity of 30 units.

2. Comparator

The applicant nominated ConvaTec Active Life One-Piece Convex Urostomy (SAS code 3628Y) from its own range, which is currently listed in subgroup 3(b), at the unit price of \$6.373 with a maximum monthly quantity of 30 units as the comparator.

3. Background

This was the Stoma product Assessment Panel (SPAP)'s first consideration of this product.

4. Clinical Place for the Product

The proposed product provides as an alternative for users requiring a one-piece urostomy pouch with convex baseplate. The product is a direct substitute for the comparator currently available in subgroup 3(b).

5. SPAP Comment

Clinical Analysis

The Panel noted that the proposed product includes cut-to-fit and pre-cut systems in a range of baseplate opening sizes to ensure optimal fit. The Panel also noted that the proposed product provides a discreet tapered wafer with integral border, anti-reflux design, a viewing window and a secure urine outlet valve.

The Panel noted that these products have been available in Europe since 2009 under the brand name Stomocur Uro Soft Convex and that no reports of adverse incidents were submitted.

Economic Analysis

Not undertaken.

Financial Analysis

Listing of this product would be on a cost-minimisation basis compared with the nominated comparator product in subgroup 3(b) of the SAS Schedule. It is therefore unlikely that there would be any budgetary impact for the SAS as a consequence of listing this product under the conditions requested by the applicant.

6. SPAP Recommendation

The SPAP recommended that the Esteem[®] + Convex Urostomy, including seven variants, be listed in subgroup 3(b) of the SAS Schedule at the benchmark unit price \$6.373, with a maximum monthly quantity of 30 units.

7. Context for Decision

The SPAP helps decide whether stoma products should be subsidised and, if so, the conditions of their subsidisation in Australia. It considers submissions in this context. An SPAP decision not to recommend listing or changes to a listing does not represent a final SPAP view about the merits of a particular stoma product. A company can resubmit to the SPAP following a decision not to recommend listing or changes to a listing. The SPAP is an advisory committee and as such its recommendations are non-binding on Government. All SPAP recommendations are subject to Cabinet/Ministerial approval.

8. Applicant's Comment

ConvaTec (Australia) Pty Ltd agrees with the SPAP's recommendation contained in the Public Summary Document.